Press releases

Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the PREVAIL confirmatory study, designed to gain U.S. Food and Drug...

Boston Scientific Corporation (NYSE: BSX) welcomes final passage today by the United States Senate of "The Food and Drug Administration Safety and...

Natick, MA (June 14, 2012) –Warren Wang has been appointed Vice President and Managing Director of Boston Scientific Corporation’s (NYSE:BSX) operations in China. Mr. Wang is responsible for...

Next-generation wireless remote patient management system enabled for INGENIO™ family of pacemakers is now in use in Europe

Adds first and only commercially available subcutaneous ICD technology that offers new life-saving therapy option to patients at risk of sudden cardiac arrest.

Medical device tax would stifle innovation

Event to be webcast live and will include detailed review of Bronchial Thermoplasty opportunity.

PROMUS Element plus stent system offers physicians the broadest array of Everolimus drug-eluting stent lengths and diameters in the U.S.

Devices projected to have nearly twice the longevity of comparable products

Indication provides new therapeutic option for extraction of difficult-to-manage biliary stones

Seven abstracts and data analyses to be presented May 19 – 22 in San Diego.

Two-year clinical data demonstrate low adverse event rates, including no myocardial infarction or stent thrombosis, for the Boston Scientific 2.25 mm PROMUS Element Platinum Chromium Stent

New self-expanding Nitinol stent offers balance of flexibility and radial strength for enhanced performance in iliac stenting procedures.

Follow-up data from EVOLVE Trial presented at EuroPCR.

Results of REPRISE I study suggest device minimizes aortic regurgitation

Innovative stent designed to treat peripheral vascular lesions for stenoses in arteries above the knee.

Collaboration expected to improve access to imaging data used to treat patients.

Results presented at Heart Rhythm Society from ASA Plavix study evaluating Boston Scientific Left Atrial Appendage Closure Device.

Clinical presentations to include 12-month outcomes data from EVOLVE trial and results of the REPRISE I trial.

Advanced pacemaker platform designed to treat chronotropic incompetence, which affects up to 42 percent of pacemaker patients.

Clinical presentations will provide new insights for physicians who treat patients with heart disorders including sudden cardiac arrest, atrial fibrillation and heart failure.

A live webcast and replay of the May 8 session will be available. Read more.

Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions.

REPRISE I Trial Results to be Presented at EuroPCR 2012

Fesults “demonstrate continued progress towards improving our future growth profile and in executing our strategic plan," said CEO Hank Kucheman.

Device is intended for use in a wide range of electrophysiology (EP) procedures to facilitate the introduction and placement of diagnostic and therapeutic catheters within the heart.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 2012 on April 19. Learn how to tune in or watch the replay.

Advanced devices designed to treat chronotropic incompetence, which affects up to 42 percent of pacemaker patients.

BackStop Gel is a water-soluble polymer that urologists inject into the ureter to form a plug behind the stone, preventing migration of stone fragments of all sizes.

CTAF report supports safety, efficacy and positive health outcomes of bronchial thermoplasty for treatment of patients with severe asthma.

HORIZONS II AMI trial to enroll up to 10,000 patients worldwide, making it the largest randomized trial to study coronary stents in heart attack patients.

Results were presented at the American College of Cardiology Annual Scientific Sessions.

Quantitative Coronary Angiographic outcomes from PERSEUS and PLATINUM clinical trials presented at ACC 2012.

Company's WallFlex Biliary Stents now available with a Transhepatic delivery system for use by interventional radiologists in treating obstructions within the biliary tract.

Data to include two-year results from the PLATINUM Workhorse clinical trial, with follow-up data on PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent.

Priority Health and HealthPartners issue new medical policies to cover catheter-based procedure shown to provide long-lasting control of severe asthma.

Radiofrequency ablation catheter designed to treat a variety of arrhythmias.

Company gains first and only commercially available subcutaneous ICD technology to offer lifesaving therapy to patients at risk of sudden cardiac arrest.

Five-year contract extends the existing commercial agreement, promotes continued investments in laser and fiber product development for urologic applications.

Next-generation coronary stent employs innovative alloy designed to improve acute performance.

TELIGEN family of ICDs, designed to treat sudden cardiac death, are the smallest and thinnest high-energy devices available in China.

ION™ and TAXUS® Liberte® Paclitaxel-Eluting Stent Systems now approved for treating patients with acute myocardial infarction in the U.S.

A live webcast of the session on February 29, 2012 will be available. Learn how to tune in or watch the replay.

Moody's Investors Service has upgraded the Company's corporate credit rating to an investment grade rating, Baa3, with a stable outlook.

TruePath™ CTO Device designed to facilitate crossing of chronic total occlusions.

A webcast of the February 15, 2012 session will be available. Learn how to tune in live or watch the replay.

Studies published in peer-reviewed medical journals

New device offers excellent flexibility and large size for acquiring tissue samples.

World’s first and only 16-contact percutaneous lead is the latest innovation in company’s comprehensive percutaneous lead portfolio.

“We continue to make progress with new product introductions, cost-saving initiatives and a strengthened presence in emerging markets," said CEO Hank Kucheman.

Platinum chromium coronary stent with enhanced delivery system now available in Europe and other international countries.

Pan-Asia business model to help drive growth by leveraging best practices in the region and the strength of local talent while collaborating with healthcare professionals and regulatory agencies throughout the region.

NICE report supports safety and effectiveness of Alair® System

Johnson and Johnson's patents found invalid

Boston Scientific will webcast its conference call with financial results for Q4 and full year ended December 31, 2011. Learn how to tune in or watch the replay.

Nine-month data presented at ISET support safety and efficacy of Epic Stent in iliac stenting

CMS pass-through payment and new CPT®[1] codes established for catheter-based procedure to treat severe asthma.

Boston Scientific will participate in the healthcare conference on January 11, 2012. Learn how to watch the webcast or replay.

Boston Scientific's third new peripheral balloon catheter introduced in 2011 strengthens Company's position as a global leader in peripheral angioplasty balloons.

Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval of the Infinion™ 16 Percutaneous...

Extended ICD/CRT-D program offers warranties up to 10 years

New family of cardiac devices offers excellent longevity and industry's longest warranty.

Approval marks transition to internally manufactured everolimus-eluting stent in the U.S.

Boston Scientific will participate in the healthcare conference on November 30, 2011. Learn how to watch the webcast or replay.

Innovative left atrial appendage closure device offers proven alternative to anticoagulant drugs for patients in atrial fibrillation at high risk for stroke.

Legislation seeks to improve the ability of companies like Boston Scientific to safely, efficiently and predictably bring new technologies to market.

Positive results from COBRA trial presented at TCT

EVOLVE trial evaluates fourth-generation everolimus-eluting coronary stent with ultra-thin abluminal bioabsorbable polymer.

Carotid WALLSTENT shown to be a safe alternative to carotid endarterectomy (CEA) in patients with carotid artery stenosis who are at increased risk for surgery.

PLATINUM Long Lesion clinical results presented at TCT show no cardiac death, heart attack or stent thrombosis at one year.

Long-term results presented from two studies evaluating advanced paclitaxel-eluting stent.

Multi-center study published in Gastrointestinal Endoscopy is largest ever reported on peroral cholangioscopy.

Clinical presentations to include 12-month data on fourth-generation SYNERGY™ Stent.

Video demonstration of CardioTeach™ app by Dr. Kenneth Stein available online

“Boston Scientific’s POWER strategy is the right top priority for the entire leadership team," said CEO Hank Kucheman.

BWallFlex study includes patients with bile duct strictures associated with post liver transplant anastomosis, prior abdominal surgery and chronic pancreatitis.

Company's everolimus-eluting platinum chromium stent now being marketed in world's second-largest DES market.

Legislation is intended to streamline the medical device review and approval process, reduce regulatory delays and help new medical technologies safely and more expeditiously reach patients.

Boston Scientific will webcast its conference call with financial results and business highlights for Q3 2011 on Thursday, October 20. Learn how to tune in.

Third-generation bare-metal stent designed to offer improved acute performance in treating patients with coronary artery disease

Study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients

U.S. Court of Appeals for the Federal Circuit found in favor of the Company in a 1998 patent infringement suit involving Johnson & Johnson

Ultra-low profile, highly deliverable balloon dilatation catheter offers physicians exceptional performance in peripheral angioplasty procedures.

Company supports women's health through online community launched by American Urogynecologic Society (AUGS) at annual meeting.

Mahoney Has Served as Worldwide Chairman, Medical Device and Diagnostics Group, Johnson & Johnson

Boston Scientific Corporation (NYSE: BSX) today issued the following statement from John Pedersen, Senior Vice President and President of the Company's...

A live webcast and replay will be available. Read more.

Company also introduces industry's first iPhone®/iPad® app for healthcare professionals using SCS

Company's fully covered metal stent now approved in Canada for use in treating benign biliary strictures

U.S. Court of Appeals for the First Circuit has affirmed the dismissal of a securities fraud case in connection with the 2004 recall of the TAXUS® Express2 Paclitaxel-Eluting Coronary Stent System

Investment supported by grant funding from Government through IDA Ireland

Company also announces new share repurchase, China investment and restructuring program

"This repurchase program reflects our confidence in the strength of the Company's long-term business prospects, earnings growth potential and our ability to generate strong cash flow," said Ray Elliott, President and CEO

Investment to support development of local manufacturing capabilities and training center

Fitch Ratings upgrades Company's corporate credit rating to an investment grade rating, BBB-, with a stable outlook

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 2011 on Thursday, July 28. Learn how to tune in.

European ASTI study to evaluate new nitinol stent to treat carotid artery disease

Recently-launched PTA catheter, designed for a wide range of peripheral angioplasty procedures, expected to be site’s biggest launch this year

Expanded Heredia plant to manufacture a broad line of medical devices

Comprehensive identifies pain as a major US health problem and lays the foundation for chronic pain care, research and education for the next decade.